This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (109)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of a Prospective Randomized Placebo-Controlled Clinical Trial

Pharmacological Therapy for Macular Degeneration Study Group

Arch Ophthalmol. 1997;115(7):865-872.

Abstract
Background
Interferon alfa-2a has been shown to be effective as an antiangiogenic agent for several systemic human angiogenic disorders and has shown antiangiogenic activity in the laboratory.

Objective
To evaluate the safety and efficacy of interferon alfa-2a for the treatment of choroidal neovascularization secondary to age-related macular degeneration.

Methods
A randomized, placebo-controlled, parallel, multicenter double-blind trial was performed at 45 ophthalmic centers worldwide. Four hundred eighty-one patients were randomly assigned to 4 treatment groups: placebo or interferon alfa-2a (Roferon-A), 1.5, 3.0, or 6.0 million international units (MIU). Visual acuity testing, clinical examination, fluorescein angiography, and indocyanine green angiography were evaluated, with the primary end point being a comparison of the number of patients who experienced a loss of 3 lines or more of vision at 1 year.

Results
At 52 weeks, 40 (38%; 95% confidence interval, 29%-48%) of 105 placebo-treated patients had lost at least 3 lines of vision (with 12% unavailable for follow-up), compared with 142 (50%; 95% confidence interval, 44%-55%) of 286 in the 3 active treatment groups combined. The difference in proportions was not statistically significant. However, a pairwise comparison of these proportions for the placebo group vs the group that received interferon alfa-2a, 6 MIU (with 26% unavailable for follow-up), showed a statistically significant difference in favor of the placebo group (P=.02) and a nearly significant difference for the placebo vs the 1.5-MIU group (P=.05) (with 16% unavailable for follow-up), again favoring the placebo group. The 3-MIU group (with 22% unavailable for follow-up) did not show a statistically significant difference in pairwise comparison (P=.48), suggesting that a dose-response relationship was not evident.

Conclusion
Interferon alfa-2a provides no benefit as a treatment for choroidal neovascularization secondary to age-related macular degeneration and may be associated with a poorer visual outcome when given at a dose of 6 MIU. However, the absence of a clear dose-response relationship raises the possibility that the observed differences result from chance.

Footnotes
A complete list of the members of the Pharmacological Therapy for Macular Degeneration Study Group appears on pages 870 and 871.

Affiliations of the authors are given in the acknowledgment section at the end of the article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age-related macular degeneration: diagnosis and management
Cook et al.
Br Med Bull 2008;85:127-149.
ABSTRACT | FULL TEXT  

An Ethical View of the Ranibizumab and Bevacizumab Controversy--Reply
Miller
Arch Ophthalmol 2008;126:286-287.
FULL TEXT  

Uncertain Compassion in Using a Drug Before the Risks and Benefits Are Known
Narayanan and Kuppermann
Arch Ophthalmol 2006;124:1032-1034.
FULL TEXT  

Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances
Campochiaro and the First ARVO/Pfizer Institute Working Group
IOVS 2006;47:462-474.
FULL TEXT  

Accelerated Drug Development Through Combined Phase 2/3 Clinical Trial Design
Cunningham et al.
Arch Ophthalmol 2004;122:1043-1044.
FULL TEXT  

Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Nambu et al.
IOVS 2003;44:3650-3655.
ABSTRACT | FULL TEXT  

Helping Patients Experience the Emotions of Vision Loss
Fong et al.
Arch Ophthalmol 2003;121:1041-1042.
FULL TEXT  

Severe interferon associated retinopathy
Tu et al.
Br J Ophthalmol 2003;87:247-248.
FULL TEXT  

Macular Translocation With 360{degrees} Retinotomy for Exudative Age-Related Macular Degeneration
Aisenbrey et al.
Arch Ophthalmol 2002;120:451-459.
ABSTRACT | FULL TEXT  

Targeting of Interferon to Choroidal Neovascularization by Use of Dextran and Metal Coordination
Yasukawa et al.
IOVS 2002;43:842-848.
ABSTRACT | FULL TEXT  

Monoclonal Antibody-Mediated Drug Targeting to Choroidal Neovascularization in the Rat
Kamizuru et al.
IOVS 2001;42:2664-2672.
ABSTRACT | FULL TEXT  

Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin
Mori et al.
Am. J. Pathol. 2001;159:313-320.
ABSTRACT | FULL TEXT  

Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy
SOUBRANE and BRESSLER
Br J Ophthalmol 2001;85:483-495.
FULL TEXT  

Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation
Newsom et al.
Br J Ophthalmol 2001;85:173-178.
ABSTRACT | FULL TEXT  

New Soft-Tipped Instruments for Foveal Translocation Surgery With 360{degrees} Retinotomy
Ohji et al.
Arch Ophthalmol 2000;118:1422-1424.
ABSTRACT | FULL TEXT  

Extracts from "Clinical Evidence": Age related macular degeneration
Arnold and Sarks
BMJ 2000;321:741-744.
FULL TEXT  

Age-Related Macular Degeneration
Fine et al.
NEJM 2000;342:483-492.
FULL TEXT  

Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration
Chiquet et al.
Br J Ophthalmol 1999;83:923-928.
ABSTRACT | FULL TEXT  

Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study
Donati et al.
Br J Ophthalmol 1999;83:646-651.
ABSTRACT | FULL TEXT  

Alternative therapies in exudative age related macular degeneration
CHONG and BIRD
Br J Ophthalmol 1998;82:1441-1443.
FULL TEXT  

Cytokine Therapy in Eye Disease
Okada
Arch Ophthalmol 1998;116:1514-1516.
FULL TEXT  

What Is the Future of Research in Age-Related Macular Disease?
Bird
Arch Ophthalmol 1997;115:1311-1313.
ABSTRACT  

We Are Very Spoiled
Fine and Maguire
Arch Ophthalmol 1997;115:915-916.
ABSTRACT